International Journal of Cancer

Cover image for Vol. 135 Issue 6

Editor-in-Chief: Professor Peter Lichter, DKFZ, Germany

Impact Factor: 6.198

ISI Journal Citation Reports © Ranking: 2012: 23/197 (Oncology)

Online ISSN: 1097-0215


Author Guidelines


QUICK LINKS

Online submission [req]
Author agreement form [upon acceptance]
Cell line confirmation form
Open access order form
NIH Public Access policy
Author services



Author Guidelines


NEW UPDATE: JANUARY 2012

Starting in February 2012, IJC ask authors to ensure that their manuscripts meet the journal’s formal requirements as concerns presentation, formatting and other accompanying documentation upon submission. In the event that papers do not fulfill these formal requirements, the editorial staff will “unsubmit” the manuscript. Authors will be asked to either upload files as needed or correct/revise the paper accordingly. Peer-review will not commence until the requirements have been met.

This applies in particular to:

  • Abstract (should not be divided into paragraphs, i.e., structured; Sect. 4.1)
  • A brief description of the novelty and impact of your paper, both on the ScholarOne submission page and on the title page of your paper (Sect. 4.1)
  • Word count for body of text, i.e., Introduction through Conclusion (Sects. 4.1.1-4.1.4)
  • Figure and table count (Sects. 4.1.1-4.1.4)
  • Reference count (Sects. 4.1.1-4.1.4)
  • Reference format. An updated EndNote Style sheet is available via our homepage. Reference Manager users are welcome to inquire at the editorial office concerning available tools for formatting references (Sect. 4.2)
  • Microarray data access information (Sect. 4.6.2) 8. Cell line authentication documents (Sect. 4.6.3)
1. CONTACT DETAILS

1.1 Editorial Office

We invite inquiries to the Editorial Office at any time during the editorial process. For all matters concerning pre-submission, editorial policies and procedures, and general production matters, please contact the Heidelberg editorial office:

International Journal of Cancer
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 242, V962
69120 Heidelberg, Germany
Telephone: 49-6221-42-4800
Fax: 49-6221-42-4809
E-mail: intjcanc@dkfz.de
Web: www.intjcancer.org

1.2 The Publisher

Specific questions regarding your proofs and copy editing of your manuscript can be handled by the publisher, Wiley–Blackwell. You can reach the publisher’s production department at jrnlprodIJC@cadmus.com

2. AIMS & SCOPE

The International Journal of Cancer (official journal of the Union for International Cancer Control—UICC) appears 24 times per year. International Journal of Cancer invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles, Mini-Reviews, Short Reports, and Letters to the Editor. The Research Article categories within the journal are: Carcinogenesis; Cancer Cell Biology; Cancer Genetics; Infectious Causes of Cancer; Tumor Immunology; Early Detection and Diagnosis; Epidemiology; and Cancer Therapy. Several times per year the journal also publishes special sections consisting of invited articles on a timely topic in cancer research.

International Journal of Cancer (IJC) is available online at http://www.intjcancer.org

3. MANUSCRIPT CATEGORIES

3.1 Research Articles

Full research papers should be as concise as possible, without sacrificing documentation of results. For studies on humans, a clear statement must be provided concerning informed consent, and that the study was conducted after Human Experimentation Review by the relevant committee. Research articles should fit within the categories outlined below and meet the editorial standards stated.

3.1.1 Carcinogenesis. Carcinogenesis includes studies on physical and chemical carcinogens, metabolism, repair of carcinogen-modified DNA, molecular dosimetry, and the formation, identification and quantification of carcinogens from exogenous and endogenous sources. Reports on mechanistic investigations are particularly welcome and can include both animal and human studies. The cancer-preventive potential of chemical, physical, or biological reagents also fits into this section.

3.1.2 Cancer Cell Biology. Analytical and functional data on tumor cell characterization (in vitro and in vivo) and on tumor-stroma interactions are very welcome. Immunohistochemical studies on tumor specimens should comprise reliable characterization of the immune reaction with proof of antibody specificity and selectivity. These data should be seconded by RNA expression and/or functional studies demonstrating the reliability and relevance of the histochemical findings. Confirmatory findings on additional tumor types, stages, or sites without new functional, diagnostic, or therapeutic implications are not within the scope of the journal.

3.1.3 Cancer Genetics. Genetic studies leading to the identification of factors and biochemical pathways relevant for the pathomechanism of tumors are particularly welcome. For studies concerning polymorphisms and cancer risk, a clear explanation of the biological hypothesis underlying the investigation, including possible biochemical pathways and functional relevance of genetic polymorphisms should be given. In cases of newly identified alleles, the potential functional relevance must be stated. Studies about new diagnostic tools are also within the scope if they hold promise of broad application. Regarding comprehensive data sets of genetic profiling (microarray) studies, raw data must be in a publicly available database that requires MIAME format (for example, “GEO” or “Array Express”) upon submission of a paper. Should expert reviewers of the IJC request access to these primary data, authors need to provide the confidential password that is supplied by the database provider.

3.1.4 Infectious Causes of Cancer. Contributions to this section should cover novel observations on the role of viral, bacterial, or parasitic infections in human cancers. Mechanistic aspects concerning direct or indirect modes of infectious carcinogens will be of particular interest. Functions of viral oncogenes as well as the discovery of new viruses or other infectious pathogens with growth-stimulating properties for infected cells or tissues will be considered. Indirect modes of carcinogenesis by infections are clearly of interest for the journal. Seroepidemiological and immunological studies related to infectious carcinogens will be considered if they present new data or demonstrate novel links between tumors and infections. The development of vaccines directed against tumor-linked infectious agents and their application is also of substantial interest. We also consider submissions on oncolysis by infectious agents.

3.1.5 Tumor Immunology. This section covers novel findings on the immunological relationship between tumor and host, including all aspects of cellular and humoral immunity directed at tumor and associated stromal cells. Experimental and clinical studies based on in vivo, ex vivo and in vitro analysis will be considered. Particularly welcome are studies on new and improved preventive and therapeutic approaches exploiting innate and adaptive immune effects or mechanisms, such as vaccines. The potential relevance of newly identified tumor cell-associated T cell epitopes should be validated by functional in vivo studies.

3.1.6 Early Detection and Diagnosis. This section covers the area of predictive and diagnostic markers from molecular biology studies. We invite papers that explore the development and application of nucleic acid-based, protein-based, serological, and other approaches that identify biomarkers linked to cancer as well as the results of current investigations using other novel molecular probes as diagnostic and prognostic indicators for cancer detection and therapy.

3.1.7 Epidemiology. Studies in human populations providing evidence that i) agents/exposures/host-factors pose a carcinogenic risk or are protective; ii) attempt to establish their causal role; iii) identify (sub-) populations at greatest risk; and iv) host–environment interactions are welcome. These include molecular cancer epidemiology approaches, in which advanced laboratory methods are integrated. Randomized trials, case–control studies, cohort studies, studies of screening and diagnostic tests and intervention studies will be considered. Each manuscript should clearly state an objective or hypothesis, the design and methods (including the source of patients or participants with inclusion/exclusion criteria).

3.1.8 Cancer Therapy. Reports on new advances in cancer therapy in humans are welcome, especially the results of well-designed randomized trials involving novel therapy strategies or those implicating molecular response indicators to classic therapeutics. If the authors are describing the results of a randomized controlled trial, we recommend use of the style guidelines in describing the study population (see JAMA 1996;276:637–639). If the authors are describing the results of observational studies of therapy, the standards applicable in observational studies in epidemiology should be followed (see above). IJC does not publish case reports.

3.2 Mini-Reviews

Though Mini-Reviews are primarily commissioned by the Editors, pre-submission proposals will be considered. The Editors will then indicate whether the review is of potential interest for the journal.

3.3 Letters to the Editor

Comments on published papers and controversial issues, also including negative data that are of general interest or that contradict commonly accepted concepts or hypotheses, will be considered for publication as Letters to the Editor. In the former case, the Editors may invite letters containing pertinent and interesting observations concerning cancer research in general, reports on new observations or pilot studies that do not justify a full research article, or comments on published papers will be considered for publication. In the latter case, the Editors may invite the authors of the paper being questioned to respond. Both Letters may then be published, if found to be of interest to the Editors.

3.4 Short Reports

Manuscripts containing pertinent and interesting observations concerning cancer research in general and reports on new observations or studies that do not warrant publication as a full research article will be considered for the Short Report section. These articles will undergo full peer review.

3.5 Special Section Papers

Special Section Papers are commissioned by the Editors. Authors will be given individual guidance in preparing their manuscripts.

4. MANUSCRIPT PREPARATION

4.1 Manuscript text

All manuscripts should be written in English (either British or American spelling) and include a title page (with short title, corresponding author contact information—address, fax, and email—, three to five key words, abbreviations used, and the appropriate article category). Research Articles and Short Reports should also include a brief description (max 75 words) of the novelty and impact of the work on the title page of the paper. All manuscripts except Letters should provide a non-structured summary/abstract (maximum 250 words).

Please note that we cannot process your paper if it does not meet all our formal requirements. In such cases, the editorial staff will “unsubmit” the manuscript before it is processed any further to provide authors with the opportunity to either upload files as needed or correct/revise the paper accordingly.

4.1.1 Research Articles. Research Articles should be divided into the following sections:

  • Title page
  • Abstract
  • Introduction
  • Material and Methods
  • Results
  • Discussion
  • Acknowledgments
  • References
  • Tables
  • Figure legends

Research Articles should not exceed 5,000 words in length (excluding references) and should be limited to a maximum of 6 tables/figures and 50 references. Please note, page charges are applied to articles which exceed 8 typeset pages (see 8.1).

4.1.2 Mini Reviews. Mini Reviews should not exceed 4,000 words in length (excluding references) and should be limited to a maximum of 6 tables/figures. There is no limit on the number of references.

4.1.3 Letters to the Editor. Letters should begin with a title page (with the heading Letter to the Editor and corresponding author contact information—address, fax, and email). Length should not exceed 1,000 words plus one figure/table and 10 references.

4.1.4 Short Reports. Short Reports should begin with a title page (with the heading Short Report and corresponding author contact information—address, fax, and email). Generally, these articles should contain the same sections as Research Articles. Short reports should not exceed 2,500 words in length (excluding references) and should be limited to a maximum of 3 tables/figures and 25 references.

4.1.5 Special Section Papers. These papers are commissioned by the Editors. Authors of Special Section Papers will be given individual guidance in preparing their manuscripts.

4.2 References

References are listed in a separate reference section immediately following the text. All references must be verified by the corresponding author who submits the manuscript to IJC. Follow the style of the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals”1 for reference format and Index Medicus2 for standard journal abbreviations (please see examples below). Number references sequentially in the order cited in the text; do not alphabetize. A reference cited only in a table or figure is numbered in the sequence established by the first mention in the text of the table or figure containing the reference.

Reference to a personal communication or to a manuscript categorized as in preparation or submitted for publication is discouraged. However, if such a reference is essential and refers to a written communication, the source is cited parenthetically in the text (not in the reference section) with the comment "unpublished data" or "personal communication”. Written permission from the source that is cited must be sent to the Editorial Office. Reference to a paper accepted but not yet published is listed in the reference section as “in press”. “In press” references must be updated by the authors as soon as publication data are available.

For review, please provide names of all authors in a reference when there are 12 or fewer; if there are 13 or more authors, you may list the first 12, followed by “et al.”. At proof stage, however, this will be reduced to 3 names to accommodate our print publication layout.

Journal references shall include the specified information listed in the following order: authors, article title and subtitle, journal abbreviation, year, volume number in Arabic numerals, and inclusive pages:

  1. Edmonds MD, Hurst DR, Vaidya KS, Stafford LJ, Chen D, Welch DR. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer 2009;125:1778–85.

Book references are listed as follows: authors, title, edition (if other than the first), volume (if more than one), city, publisher, year, pages:

  1. Sobin LH, Wittekind C, eds. TNM classification of malignant tumors, 5th ed. New York: Wiley-Liss, 1997. 227p

When referencing a book chapter, the order changes as follows: authors of the chapter, title of the chapter, "In:" editors/authors of the book, title of the book, edition (if there are more than one), volume (if there are more than one), city, publisher, year, and inclusive pages of the chapter:

  1. Luketich JD, Ginsberg RJ. Diagnosis and staging of lung cancer. In: Johnson BE, Johnson DH. Lung cancer. New York: Wiley-Liss, Inc., 1995:161–73.

4.3 Figures

Authors should upload high-quality graphic data for figures. For use in the peer review process, the Editorial office accepts ppt, gif, tif, jpg, and eps files. Figures may be submitted in these formats. However, the preferred format is tif or eps, which would be required when the paper is accepted. For accepted papers, figures can also be supplied in ppt format if they have passed the Rapid InspectorTM test. For line drawings in print and for supplementary material, pdf format is also acceptable.

Figures should be numbered using Arabic numerals. All figures should be cited in the text. Each figure requires a separate legend.

All color figures will be reproduced in full color in the online edition of the journal at no cost to authors. Authors are requested to pay the cost of reproducing color figures in print (see 8.2).

4.4 Tables

Tables can be included in the main document or submitted as separate files. They are numbered using Arabic numerals. Submit tables preferably in doc or rtf format, exceptionally as xls, tif or eps. All tables should be cited in the text. Each table requires a separate legend.

4.5 Additional supporting information for online publication

Material that is not suitable for print publication such as very long tables, database information, movies, etc., can be published online as additional supporting information. The final decision to do so, however, lies with the Editors. Please submit camera-ready files for this material as it will not be edited or altered in any way by the publisher.

4.6 Special requirements

4.6.1 Sponsorship and funding/financial disclosure. The Acknowledgments section is an appropriate place to recognize coworkers, indicate funding sources, and disclose information about affiliations and potential conflicts of interest (for example, commercial affiliations, patent-licensing arrangements). IJC subscribes to the guidelines published by Davidoff et al. in the New England Journal of Medicine3 and to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals”2. Authors must state all their sources of funding and any other financial and personal relationships that might bias their work. If the research reported in the manuscript has received partial or complete funding from commercial sponsors, the authors must also include a statement to that effect. The Editors reserve the right not to consider a manuscript if a sponsor has asserted control over the authors' right to publish their research results. Therefore, if the authors have a potential financial or personal conflict of interest, they must submit the Conflicts of Interest form.

4.6.2 Gene names and genetic profiling data. Please mark all gene names in italics. However, only the gene names should be written in italics, to distinguish them from gene products, gene segments, clusters, families, complexes, or groups. Authors should only use the official gene name as assigned by the respective gene nomenclature committee.

Regarding comprehensive data sets of genetic profiling (microarray) studies, raw data must be in a publicly available database that requires MIAME format (for example, “GEO” or “Array Express”) upon submission of a paper. Should expert reviewers of IJC request access to these primary data, authors need to provide the confidential password that is supplied by the database provider.

4.6.3 Authentication of cell lines. As a consequence of the increasing use of cross-contaminated cell lines, the Editors of IJC have taken measures to ensure that papers accepted for publication are not based on misidentified cells. Therefore, studies dealing with established human (tumor) cell lines must provide authentication of the origin and identity of the cells. This is best achieved by DNA (STR) profiling (see below). Authentication is required for all established human tumor cell lines that were acquired more than 4 years before the date of submission of the manuscript, including those provided from other laboratories or that were generated in the course of the present or a previous own study.

For authentication, authors should first check the list of confirmed misidentified and cross-contaminated cell lines to see whether the cell line they used is already known to be misidentified. Authors can either perform the profiling in their own laboratory (e.g., using a commercially available kit) or use the service provided by an approved laboratory or cell bank (click here for a list of optional service providers). The DNA profile then needs to be cross-checked with the DNA profile of the donor tissue (in case of a new cell line) or with the DNA profile of other continuous cell lines such as provided by the data bank available through www.dsmz.de/fp/cgi-bin/str.html (personal registration required). We ask authors to sign and upload the form we have provided as confirmation that profiles for human cell lines used in the study have been compared with this list.

The following cell lines are presently exempt from this rule:

  • Cell lines acquired within the last 4 years from a commercial source that guarantees cell line authenticity through in-house quality control measures. It is sufficient to provide their certificate/documentation, including the purchase order or invoice (N.B.: A published paper does not constitute sufficient documentation).
  • Short-term cultures of human tumors
  • Murine/rat/rodent cell lines (as a catalog of DNA profiles is not yet available)
  • Tumor cell lines established in the course of the study that is being submitted. However, we strongly advise authors to establish a profile for these cell lines because, as outlined above their cell lines because as soon as the line has been in use for more than 4 years, authentication will be required again.

4.6.4 Medical writing assistance policy
IJC subscribes to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals issued by the International Committee of Medical Journal Editors2. Accordingly and as outlined therein, “authors should identify individuals who have provided writing or other assistance and disclose the funding source for that assistance” in the Acknowledgments section of the manuscript. We do not accept mini reviews or editorials for which writing assistance was procured.

4.6.5 Policy on Managing Potential Scientific Misconduct Reported to the International Journal of Cancer
Scientific misconduct is a serious allegation and poses a great challenge to the scientific community. Inherent to the problem is also the danger of prejudging involved parties. In response to the increase in reports of scientific misconduct to editors and publishers and being publicized via the internet, IJC has established a policy concerning the disclosure of any such allegations reported to our journal so as to promote best practice in dealing with them objectively. IJC endorses the ICMJE2 requirements and handles each case by following the COPE guidelines. However, for reasons of fairness and transparency and in reciprocal good faith concerning confidentiality and accountability, anyone who will report potential misconduct to us must state their name and affiliation and disclose the basis for the allegation. Any further information that can be provided would be helpful in investigating such allegations..

5. ONLINE SUBMISSION

5.1 Original submissions

We remind you that in submitting to IJC you agree that your work is original in presentation and content and that the work has neither been published elsewhere — including being posted on any site on the Internet — nor is simultaneously under submission as a complete paper with another journal.

Please submit all new manuscripts online. Individual files should be uploaded for the text (doc or rtf format), tables (doc or rtf for text or tif or eps for graphics) and figures (tif or eps). You do not need to mail any hard copies. Launch your web browser and go to http://mc.manuscriptcentral.com/ijc-wiley. Check for an existing account. If you are submitting for the first time, create a new account. Follow the step-by-step instructions for submission. Please note that the paper should be submitted by or on behalf of the corresponding author so that he/she receives all correspondence via ScholarOne Manuscripts.

At the end of a successful submission, a confirmation screen with a manuscript number will appear and you will receive an e-mail confirming that the manuscript has been received by the journal. If this does not happen, please check your submission and/or contact technical support at via “Get Help Now”.

5.1.1 Cover letter. Please introduce your work in a cover letter in which you address the following questions:

  • What is the aim of the study?

  • What are the significant and novel findings?

  • How do these findings relate to the present state of the field?

5.1.2 Authorship and conflict of interest disclosure. Upon submission, the journal requires that the Corresponding Author ensures and takes responsibility that all co-authors agree to the submission to IJC and agree with the content and presentation of the paper. The Corresponding Author must also indicate at that time whether any author has a potential conflict of interest as per our instructions. Space is provided for this on the ScholarOne Manuscripts submission page. Please note that upon acceptance, we require pen-and-paper signatures from all authors on our Author Agreement Form.

5.1.3 Electronic Copyright Transfer Agreement (eCTA). Upon manuscript acceptance, the Corresponding Author must complete the electronic Coyright Transfer Agreement (eCTA) form. Please see Section 7.1 for further details.

For NIH employees only: Wiley–Blackwell will accept the NIH Publishing Agreement (click here for further information).
For NIH grantees: please take note of the information in the check box on the eCTA regarding deposition in PubMed Central.

5.1.4 Letter of permission. Permission is required from the appropriate investigators when “personal communication” or “unpublished data” is cited in the manuscript, or from another publisher if previously published material has been used in the manuscript.

5.1.5 Downloading forms. All the required forms are available on our homepage www.intjcancer.org under “For authors”.

5.2 Submission of revised manuscripts

If you have been invited to submit a revised manuscript, please submit it online via your author center. Instructions can be found there. Enter your point-by-point responses to the associate editor and reviewers separately at the “View and Respond” button. Upload only one copy of the paper in which all changes have been underlined or marked.

Please note that papers that have received a decision of “resubmit” should be resubmitted as a NEW manuscript. A point-by-point response can be included in the cover letter or uploaded as “supplementary material” for the paper. Please cite the number of the original paper in your cover letter.

6. EDITORIAL PROCESS

6.1 Summary

Submissions meeting our formal requirements are all assessed initially by the Editors. A selection of papers is then sent for external review to experts in the field. When a decision is reached, a decision letter is sent to the authors by email and the decision is posted on IJC’s ScholarOne Manuscripts website (http://mc.manuscriptcentral.com/ijc-wiley), where the comments of the referees can also be viewed. Decision letters for papers not sent for review are also sent by email and the decision also posted. To aid in manuscript peer review, we invite authors to suggest potential reviewers for their paper (including address and email) as part of the online submission procedure. The authors also have the option of naming non-preferred reviewers. Receipt of a manuscript is acknowledged by email.

6.2 Rejected papers

Papers may be rejected either based on the opinions of the Editors or based on the comments of external reviewers. Papers not reaching a high enough level of priority or not fitting within the scope of the Journal will be returned to authors without detailed comments. In some cases, the authors of a paper rejected by IJC may be offered the option of having the paper, along with any related peer reviews, automatically transferred for consideration to the Editor of Cancer Medicine (www.cancermedicinejournal.com).

6.3 Revisions requested

If the Editors and the reviewers respond positively to a paper and are interested in considering it further after additional work is included, authors will be invited to resubmit the manuscript to IJC. A decision letter will be sent by email containing the comments of the referees and/or Editors. We ask that revisions are made within 3 months. Any questions concerning the requested changes/additional work should be addressed to the Editors by fax or email before submission of the revised paper. Revised manuscripts may be returned to the original reviewers for reassessment. Therefore, the review process of the revised manuscript may take over a month in some cases. The Editors maintain the option to reject a paper in a second or third round of revision if the specific concerns have not been met or if the paper still does not meet a high enough level of priority. Please always include the manuscript number in any correspondence and on any documents.

7. ADDITIONAL INFORMATION ON ACCEPTANCE

7.1 Copyright

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement

If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp

For authors choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

The copyright terms and conditions can be previewed here.

For NIH employees only: Wiley-Blackwell will accept the NIH Publishing Agreement (for further information, see www.wiley.com/go/nihmandate). For NIH grantees: please take note of the information in the check box on the eCTA regarding deposition in PubMed Central.

7.2 Author Agreement Form

Upon acceptance, we require pen-and-paper signatures from all authors on our Author Agreement Form. Each author who has checked the box on the Author Agreement Form indicating that he/she has a conflict of interest must also submit the Conflict of Interest form (p. 2 of the Author Agreement Form). These authors must provide a statement concerning any commercial sponsorship, commercial affiliations, stock/equity interests, or patent licenses of potential financial disclosure with the work presented in the submitted paper. The paper cannot be sent to the publisher until these forms are complete. Please also note that this disclosure must be indicated in the acknowledgments section or as a footnote in the final version of the paper.

7.3 Accepted Articles

Further to acceptance in IJC, manuscripts are immediately made publicly available online. Accepted Articles have been peer-reviewed and accepted for formal publication, but have not been subject to copyediting, composition or proof correction. The service provides for the earliest possible dissemination of research data following article acceptance. Accepted Articles appear in pdf format only and are given a Digital Object Identifier (DOI), which allows them to be cited and tracked. The DOI remains unique to a given article in perpetuity and can continue to be used to cite and access the article further to print publication. More information about DOIs can be found online at www.doi.org/faq.html.

Neither the UICC nor Wiley–Blackwell can be held responsible for errors or consequences arising from the use of information contained in Accepted Articles; nor do the views and opinions expressed necessarily reflect those of the UICC or Wiley–Blackwell.

7.4 Proofs

Page proofs will be sent electronically to the Corresponding Author and should be returned to the Production Editor (jrnlprodIJC@cadmus.com) immediately. Significant textual alterations are unacceptable at proof stage without the written approval of the Editor-in-Chief, and they are likely to result in the delay of publication.

7.5 Early View

IJC is covered by the Publisher's Early View service, which allows for incremental online article publication in advance of print publication. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made subsequent to Early View publication. Early View articles can be cited and tracked by DOI.

7.6 OnlineOpen

OnlineOpen is available to authors of articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley InterScience, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, click here

Authors wishing to make their articles OnlineOpen will be required to complete the online form.

Prior to acceptance, there is no requirement to inform the Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the Journal's standard peer-review process and will be accepted or rejected based on their own merit.

7.8 Offprints

Corresponding Authors will automatically receive a free PDF offprint by e-mail. Additional offprints can be ordered on the offprint order form, which accompanies the proofs.

7.9 Note to NIH grantees

Pursuant to NIH mandate, Wiley–Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMedCentral upon acceptance. This accepted version will be made publicy available 12 months after publication. For further information, click here

8. AUTHOR CHARGES

8.1 Page charges

There is no fee for the first 8 pages of an article. A fee of US$150.00 for each page beyond the first 8 will be charged. (To calculate the number of printed pages your manuscript will become, count the number of text pages, allowing a page for each table and figure, and divide the total by 3.This gives a rough estimate.)

8.2 Color charges

Please be aware that the cost of color printing will be incurred by the author. The color fee is US$500 per page.

9. INFORMATION FOR PEER-REVIEWERS

IJC invites reviewers according to their expertise and experience in the field. Furthermore, they are asked to review within 10 days using our online system. Exceptionally, a pdf file for the paper can be provided and our scoresheet sent by email. It is helpful if a reviewer who is unable to review can suggest alternate, qualified reviewers.

As per the guidelines issued by the World Association of Medical Editors (also for further information, refer to www.WAME.org): “Reviews will be expected to be professional, honest, courteous, prompt, and constructive. The desired major elements of a high-quality review should be as follows:

  • The reviewer should have identified and commented on major strengths and weaknesses of study design and methodology.

  • The reviewer should comment accurately and constructively upon the quality of the author's interpretation of the data, including acknowledgment of its limitations.

  • The reviewer should comment on major strengths and weaknesses of the manuscript as a written communication, independent of the design, methodology, results, and interpretation of the study.

  • The reviewer should comment on any ethical concerns raised by the study, or any possible evidence of low standards of scientific conduct.

  • The reviewer should provide the author with useful suggestions for improvement of the manuscript.

  • The reviewer's comments to the author should be constructive and professional.

  • The review should provide the editor the proper context and perspective to make a decision on acceptance (and/or revision) of the manuscript.”

Recommendations about publication are appreciated and are welcomed in the comments to the Editors. However, we kindly ask that reviewers not make such recommendations in their comments to the authors. Indeed, it is our policy to edit such comments out of any communications to authors.

This journal may refer good quality papers that we are unable to accept to the open access journal Cancer Medicine (www.cancermedicinejournal.com). If the authors choose to pursue this option, their submission along with the peer reviewer reports will be transferred to the Cancer Medicine editor in order to provide the author with a rapid publication decision. Reviewers will be asked at the time of reviewing whether they agree to forward their review. Reviewers will not be contacted about their reviews by the Cancer Medicine editorial office, nor will they be asked to reevaluate a revised version of the manuscript for Cancer Medicine. A primary objective for this collaboration is to lessen the burden on the already over-stretched community of peer reviewers. If you have questions about this, please contact the journal's Editorial Office.

As regards peer review and reviewing, the journal also subscribes to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (www.icmje.org), which specifically state that “All participants in the peer-review and publication process must disclose all relationships that could be viewed as potential conflicts of interest”. Therefore, we also kindly ask reviewers to inform us if they have a potential conflict of interest in reviewing a certain paper. Please also refer to the aforementioned guidelines in full for further information.

We ask reviewers to send us three keywords that describe their area of speciality and to thus help us to further develop our reviewer database.

At regular intervals IJC publishes a list of those individuals who reviewed for us during a certain time period. Upon request, we are also willing to provide our reviewers with a letter of reference to that effect.

Footnotes

1Davidoff F, DeAngelis CD, Drazen JM, Nicholls MG, Hoey J, Hojgaard L, Horton R, Kotzin S, Nylenna M, Overbeke AJ, Sox HC, Van Der Weyden MB, Wilkes MS. Sponsorship, authorship, and accountability. N Engl J Med 2001;345:825–6.

2International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Ann Intern Med 1997;126:36–47. Update 2010 available at www.icmje.org

3National Library of Medicine. List of journals indexed in index medicus. Washington, DC: US Government Printing Office [published annually].

SEARCH

SEARCH BY CITATION